Trial Profile

A phase I study for mRNA-1172 for the prevention of Respiratory syncytial virus infections

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 14 Nov 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MRNA 1172 (Primary)
Indications Respiratory syncytial virus infections
Focus Adverse reactions
Sponsors Merck & Co

Most Recent Events

06 Nov 2019 According to a Moderna Therapeutics media release, this study is led by Merck.
07 Aug 2019 Status changed from planning to recruiting, according to a Moderna Therapeutics media release.
07 Aug 2019 According to a Moderna Therapeutics media release, the first subject has been dosed in this trial.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com